NEW YORK(GenomeWeb) – Melanoma test development firm DermTech has raised $2.4 million. 

DermTech disclosed the financing in a document filed with the US Securities and Exchange Commission earlier this week. In an email, DermTech CFO and Treasurer Steven Kemper told GenomeWeb that participants in the private financing round included existing investors. He added that the La Jolla, Calif.-based firm is launching its pigmented lesion assay and is currently testing the assay with certain US dermatologists with plans for a broader launch in the second half of this year. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.